The global bioprocess automation market was valued at an estimated $8.6 billion in 2025 and is projected to reach $22.2 billion by 2033, expanding at a 12.8% compound annual growth rate from 2026 to 2033, according to a ResearchAndMarkets.com report. Growth is being supported by rising production of monoclonal antibodies, vaccines, gene therapies and other biologics, alongside demand for greater manufacturing efficiency, stricter regulatory compliance and lower operational costs. Automation consumables and accessories, process automation hardware, software and control systems, integrated and turnkey solutions, and services and support are among the segments covered. The report also analyzes upstream and downstream processing, process development and scale-up, fill-finish and packaging automation, quality control and process analytical technology across pharmaceutical and biotechnology manufacturers, contract development and manufacturing organizations, academic institutions and laboratories. Coverage spans North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa, with country-level analysis and competitive profiles of companies including Thermo Fisher Scientific, Sartorius, Parker Hannifin, Danaher, Merck KGaA, Eppendorf, SIA Bioreactors.net, Senieer, Getinge and Repligen.